Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.
about
Biology of PXR: role in drug-hormone interactionsRole of pregnane X receptor in chemotherapeutic treatmentTargeting xenobiotic receptors PXR and CAR in human diseasesMarine invertebrate xenobiotic-activated nuclear receptors: their application as sensor elements in high-throughput bioassays for marine bioactive compoundsReverse yeast two-hybrid system to identify mammalian nuclear receptor residues that interact with ligands and/or antagonistsChallenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXRAlleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitisRifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human HepatocytesActivation of xenobiotic receptors: driving into the nucleus.Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs)Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database.Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Acetylation of pregnane X receptor protein determines selective function independent of ligand activation.In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activationSLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver.Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 geneFucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.PXR antagonists and implication in drug metabolism.A concentration addition model to assess activation of the pregnane X receptor (PXR) by pesticide mixtures found in the French diet.Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXRPregnane X Receptor and Cancer: Context-Specificity is Key.Orphan nuclear receptors as targets for drug development.Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond.Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors.Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery.Affinity purification using recombinant PXR as a tool to characterize environmental ligands.Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.LASSO-ing Potential Nuclear Receptor Agonists and Antagonists: A New Computational Method for Database ScreeningExploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods
P2860
Q26822721-A7B9700D-4816-499A-9958-8B7E73F51ECCQ26827398-CED274FD-B9DD-49AE-A46C-F13F070C6451Q27012669-192A111F-0866-4E37-BC5C-E0E589816719Q27022545-9E388CB7-D8B3-4DEC-A2FB-7F368E94F505Q28303230-A1B4884E-7CF9-4AE4-B225-8F87E99FFB5CQ28472135-AC42F515-3F3C-4F8D-9281-B2A8CF9D2974Q28481350-6488EA0F-830F-4A3A-BAC4-DD6667C7113AQ28732720-CA5185F0-DEFC-4B5F-A8CD-65F6488CFF94Q33742134-2CF0D867-0935-48DD-BAC3-F45642367078Q33780204-F80CF42C-8B4D-4470-9CEA-F8AE927F37A3Q34215650-BC0BFAC6-C8FB-4776-81CB-35411FE4EAF1Q34412650-F2624C46-DE98-4017-9A0E-715F6B59A205Q34708995-FEC8B1B0-3A99-4B24-8EA7-78ED8B7FD70DQ35080467-6246B03F-4E58-417D-8AE5-38ECFDCBC823Q35198043-5CB54CB6-1777-4E1B-94F3-A62E19AB0DD2Q35489261-0602DC26-D99F-4806-9238-58D28FDE35DCQ35759931-8775A298-E75B-46E3-B230-D136739E0388Q36640752-979DFEA9-EE0D-48C7-9C1D-36EE8AAB1E03Q36801931-BEC70AE1-A923-43B5-8511-03474A6725DAQ36832670-4BB4D85F-ED5C-4765-999E-D64FB72D5938Q37243869-92F44F8E-7233-4EE6-9E41-8731B6953DE5Q37725708-6D4865A3-13BA-4F93-96E3-5CB2D69D2E67Q38074718-7657C760-B551-4923-AD12-CC17F13CFA03Q38076345-DD659E93-359C-4B02-A917-BB6FDB3C706AQ38211210-8BAAE31D-CC36-4E8F-B446-7CECE16121DAQ39416595-F7164639-2DD4-40F2-9581-4CA6A11C2B81Q39508679-8334E566-17A7-46BC-B5CE-DDC5A06439BCQ56397856-7B57AD3F-052B-4332-9135-1F65C6FA5960Q58577529-817D68C8-1CAC-4B9C-B37D-C1BB1B6FDB4D
P2860
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@ast
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@en
type
label
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@ast
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@en
prefLabel
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@ast
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@en
P2093
P2860
P50
P1476
Elucidating the 'Jekyll and Hy ...... sts or allosteric antagonists.
@en
P2093
Arunima Biswas
Sridhar Mani
P2860
P304
P356
10.1007/S11095-009-9901-7
P577
2009-05-05T00:00:00Z